" class="no-js "lang="en-US"> EUROIMMUN - Medtech Alert
Thursday, August 14, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
EUROIMMUN | Pharmtech Focus

EUROIMMUN

About EUROIMMUN

EUROIMMUN

The company was founded in 1987 from the University of Lübeck (Schleswig-Holstein, Germany). Since 2018, the US American company PerkinElmer, Inc. has been the sole shareholder of EUROIMMUN. PerkinElmer is an international leader in medical and biotechnology. The company, which has its headquarters in Waltham (Massachusetts), has 16,000 employees worldwide. With its innovative test systems, imaging and IT systems, it offers an extensive expertise in diagnostics, medical research and environmental and food analysis. PerkinElmer, Inc. is listed on the S&P-500 Index.

Related Story

COVID-19

 EUROIMMUN Launches Two Assays for the Quantification of SARS-CoV-2 Antibodies | Pharmtech Focus

EUROIMMUN Launches Two Assays for the Quantification of SARS-CoV-2 Antibodies

June 15 2022

EUROIMMUN, a PerkinElmer company, today announced the launch of two CE marked assays – the […]